Meeder Asset Management Inc Mirati Therapeutics, Inc. Transaction History

Meeder Asset Management Inc

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	SELL	$39.16 - $88.71 $939 - $2,129	-24 Reduced 92.31%	2 $0
Q1 2022 May 10, 2022	BUY	$75.82 - $150.97 $1,971 - $3,925	26 New	26 $2,000
Q4 2021 Feb 11, 2022	SELL	$132.01 - $190.29 $306,527 - $441,853	-2,322 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$132.13 - $177.45 $306,805 - $412,038	2,322 New	2,322 $410,000
Q2 2021 Aug 09, 2021	SELL	$144.0 - $179.73 $55,584 - $69,375	-386 Closed	0 $0

Q1 2021 Apr 28, 2021	BUY	$158.92 - $221.61 $61,343 - $85,541	386 New	386 $66,000
Q4 2020 Feb 09, 2021	SELL	$162.05 - $240.27 $362,829 - $537,964	-2,239 Closed	0 $0
Q3 2020 Nov 02, 2020	BUY	$113.26 - $167.27 $253,475 - $374,350	2,238 Added 223800.0%	2,239 $371,000
Q2 2020 Aug 11, 2020	BUY	$72.01 - $120.39 $72 - $120	1 New	1 $0
Q1 2020 May 15, 2020	SELL	$69.78 - $116.21 $23,655 - $39,395	-339 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$70.76 - $128.86 $424 - $773	6 Added 1.8%	339 $44,000
Q3 2019 Oct 17, 2019	SELL	$77.91 - $109.6 $90,920 - $127,903	-1,167 Reduced 77.8%	333 $26,000
Q2 2019 Aug 05, 2019	SELL	$59.49 - $104.71 $44,736 - $78,741	-752 Reduced 33.39%	1,500 $154,000
Q1 2019 Apr 16, 2019	BUY	$43.65 - $78.95 $7,202 - $13,026	165 Added 7.91%	2,252 $166,000
Q4 2018 Jan 17, 2019	BUY	$32.0 - $47.43 $7,648 - $11,335	239 Added 12.93%	2,087 $89,000
Q3 2018 Nov 02, 2018	BUY	$47.1 - $62.7 $87,040 - $115,869	1,848 New	1,848 $0
Q4 2017 Feb 02, 2018	SELL	$12.65 - $19.0 $5,009 - $7,524	-396 Closed	0 $0
Q3 2017 Oct 20, 2017	BUY	$4.7 - $11.7 $1,861 - $4,633	396	396 $5,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.